Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Teva shares rise as company offers reassurance on former flagship drug Copaxone - MarketWatch
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Is in Recovery - WSJ
Well, well,we'll...said he didn't know why “his team” invested which lowered the stock for months then just doubled his… | Dow jones companies, Investing, Dow jones
Teva Pharmaceuticals (@TevaUSA) / Twitter
